Search - tctmd.com

Displaying 161 - 180 of 329

Sort: Relevancy | Date

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Presentation TVT 2017

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

Presenter: David J. Cohen, Mark J. Russo, Adam Castano

June 16, 2017

Presentation TVT 2017

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Presenter: David J. Cohen, Mark J. Russo, Nir Uriel

June 16, 2017

Presentation TVT 2017

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Presenter: David J. Cohen, Mark J. Russo, Ran Kornowski

June 16, 2017

Presentation TVT 2017

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Presenter: David J. Cohen, Mark J. Russo, Suzanne V. Arnold

June 16, 2017

Presentation TVT 2017

Ineffective Endocarditis After TAVR: Cause for Concern?

Presenter: David J. Cohen, Mark J. Russo, Bernard Prendergast

June 16, 2017

Presentation TVT 2017

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Presenter: David J. Cohen, Mark J. Russo, Molly Szerlip

June 16, 2017

Presentation TVT 2017

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Presenter: Ran Kornowski, Mark J. Russo, David J. Cohen

June 15, 2017

Presentation Fellows 2017

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

Presenter: Sahil A. Parikh, David J. Cohen

April 08, 2017

Presentation Fellows 2017

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Manish A. Parikh, David J. Cohen

April 07, 2017

Presentation Fellows 2017

Antithrombin Therapy for the Interventionalist

Presenter: Manish A. Parikh, David J. Cohen

April 07, 2017

News Conference News ACC 2017

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

Todd Neale

March 22, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Opinion Conversations in Cardiology

Conversations in Cardiology: For Fellows, How Much Structural Heart Disease Training Is Enough?

February 27, 2017

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Advertisement

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Ineffective Endocarditis After TAVR: Cause for Concern?

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Antithrombin Therapy for the Interventionalist

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Conversations in Cardiology: For Fellows, How Much Structural Heart Disease Training Is Enough?

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content